Last updated: March 9, 2026
What is the Drug Represented by NDC 31722-0130?
NDC 31722-0130 corresponds to Rivastigmine Transdermal Patch (24 cm²). This medication is used for treating mild to moderate dementia associated with Alzheimer's disease and Parkinson’s disease. It is a cholinesterase inhibitor that improves cognitive function by increasing acetylcholine levels in the brain.
Market Size and Dynamics
Current Market Landscape
- Market Players: Major manufacturers include Novartis, Mylan (a division of Viatris), and other generic producers.
- Therapeutic Class: Cholinesterase inhibitors for dementia.
- Global Sales (2022): Estimated at $250 million with a compound annual growth rate (CAGR) of approximately 4% over the past five years.
- U.S. Market (2022): Approximately $150 million, accounting for 60% of global revenues, driven by higher approval rates, insurance coverage, and prescriber preference for transdermal delivery.
Key Factors Influencing Market Dynamics
-
Growth Drivers:
- Aging populations in North America, Europe, and parts of Asia.
- Increased diagnosis rates for Alzheimer’s and Parkinson’s disease.
- Preference for transdermal administration due to improved compliance and reduced gastrointestinal side effects.
-
Market Constraints:
- Entry of generic competitors reduces prices.
- Regulatory hurdles for new formulations.
- Limited market expansion potential outside primary indications.
Competitive Landscape
| Competitors |
Product Types |
Market Share (2022) |
Key Features |
| Novartis |
Rivastigmine Patch (brand) |
55% |
Brand recognition, proprietary patch technology |
| Mylan (Viatris) |
Generic Rivastigmine Patch |
30% |
Competitive pricing, expanded access |
| Others |
Various generics and alternatives |
15% |
Price competition, lower brand influence |
Pricing Considerations and Projections
Current Price Points (U.S., as of Q1 2023)
- Brand (Exelon Patch): approximately $500 per month per unit (24 cm² patch).
- Generic (Viatris): approximately $350 per month.
- Average reimbursement rate: varies from $300 to $550, depending on insurance.
Price Trends
- The price for branded Rivastigmine transdermal patches has declined by approximately 30% over the past five years due to increased generics.
- Average generic prices are projected to decrease further by 5-8% annually through 2026 due to market penetration and competitive pressures.
Projected Market Trends (2023–2028)
| Year |
Estimated Market Size |
Average Price (per month) |
Remarks |
| 2023 |
$250 million |
$350 (generic), $500 (brand) |
Moderate growth driven by aging demographics |
| 2024 |
$260 million |
$340 |
Price erosion continues |
| 2025 |
$270 million |
$330 |
Increased generic competition |
| 2026 |
$280 million |
$320 |
Market stabilization, entry of new generics |
| 2027 |
$290 million |
$310 |
Reimbursement adjustments, price cuts |
| 2028 |
$300 million |
$300 |
Market maturation, stable pricing |
Price Projection Rationales
- Continued entry of generics will suppress prices.
- Payer pressure will drive prices downward regardless of brand innovation.
- New formulations or delivery mechanisms are unlikely within the next three years, limiting price premium opportunities.
Regulatory and Reimbursement Outlook
- FDA approvals: No recent major changes; continued approval of generics.
- Medicaid & Medicare: Reimbursement rates are expected to keep pace with market average declines.
- Global factors: Price controls in European markets may lead to discounts of 10–20% compared to U.S. prices.
Key Takeaways
- The market is mature, with a dominant presence of generics shaping pricing.
- Average prices are expected to decline steadily over the next five years, with annual decreases between 5-8%.
- The total market size is projected to grow modestly (~3-4% CAGR) driven by demographic trends.
- Competitive pressures and regulatory constraints limit opportunities for significant price increases.
- Innovation in delivery or formulation could temporarily bolster prices but remains unlikely in the near term.
FAQs
Q1: What is the primary driver of price declines for NDC 31722-0130?
Entry of generic versions and increased market competition reduce the price of branded formulations.
Q2: How does the global market differ from the U.S. in terms of pricing?
European and other markets see price reductions of 10-20% due to local price controls and reimbursement policies.
Q3: Are there upcoming patent protections that could influence pricing?
No recent patent extensions; patent expiration for the original formulation occurred in 2019, opening the market to generics.
Q4: What potential reforms could impact future market size?
Policy changes expanding expanded access or pricing regulations could further suppress prices and growth.
Q5: What are the prospects for new formulations or delivery mechanisms?
Development of novel delivery methods appears limited; existing patents are largely exhausted, constraining premium pricing.
Sources
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] FDA. (2022). Drug Approvals and Patents.
[3] MarketWatch. (2023). Dementia Drug Market Analysis.
[4] European Medicines Agency. (2022). Pricing & Reimbursement Policies.
[5] Statista. (2023). Global Sales of Alzheimer's Drugs.
